2-萘羧酰胺 | 5651-14-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 2-萘羧酰胺
• 中文别名: 2-萘甲脒
• 英文名称: naphthalene-2-carboxamidine
• 英文别名: 2-naphthyimidamide；naphthalene-2-carboximidic acid amide；[2]naphthamidine；[2]Naphthamidin；β-Naphthoesaeure-amidin；β-Naphthenylamidin；Naphthalene-2-carboximidamide
• CAS: 5651-14-9
• 化学式: C₁₁H₁₀N₂
• mdl: MFCD05663337
• 分子量: 170.214
• InChiKey: URXJHZXEUUFNKM-UHFFFAOYSA-N

物化性质

• 熔点：
  133-136 °C(Solv: benzene (71-43-2))
• 沸点：
  328.5±25.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.9
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-萘羧酰胺 在 盐酸 、 sodium acetate 、 乙酸酐 作用下， 生成 methyl-di-[2]naphthyl-[1,3,5]triazine
  参考文献：
  名称：

  Pinner, Chemische Berichte, 1892, vol. 25, p. 1437,1626

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium amide 、 甲苯 作用下， 生成 2-萘羧酰胺
  参考文献：
  名称：

  Kirssanoff; Poliakowa, Bulletin de la Societe Chimique de France, 1936, vol. <5> 3, p. 1600,1605, 1606

  摘要：

  DOI：

文献信息

• Styrylamidines
  申请人：Mead Johnson & Company

  公开号：US04052455A1

  公开（公告）日：1977-10-04

  Styrylamidines are prepared by treating styrylsulfonylamidines with base. The styrylamidines are effective in the prevention of aggregation of blood platelets and as analgesics. Compounds of the invention are also useful as anticonvulsants, diuretics and antihypertensive agents. The styrylsulfonylamidines of the invention which serve as precursors to the styrylamidines also have analgesic properties. Illustrative of the styrylamidines of the present invention are 4-amino-N-(4-aminostyryl)benzamidine and N-(3,4-dichlorostyryl)acetamidine. An example of a styrylsulfonylamidine is N-(styrylsulfonyl)acetamidine.

  Styrylamidines是通过用碱处理styrylsulfonylamidines制备的。这些styrylamidines在预防血小板聚集和作为止痛药方面非常有效。该发明的化合物还可用作抗癫痫药、利尿剂和降压药。该发明的styrylsulfonylamidines作为styrylamidines的前体也具有止痛特性。本发明的styrylamidines的示例包括4-氨基-N-(4-氨基styryl)苯胺和N-(3,4-二氯styryl)乙酰胺。styrylsulfonylamidine的一个例子是N-(styrylsulfonyl)乙酰胺。
• Composition for the treatment of damaged tissue
  申请人：Pfizer Inc.

  公开号：US20030199440A1

  公开（公告）日：2003-10-23

  A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.

  描述了一种用于受损组织，如伤口治疗（例如愈合）的药物。该药物包括包含以下成分的组合物：（a）生长因子；和（b）抑制剂；以及可选的（c）药用载体、稀释剂或赋形剂；其中抑制剂可以抑制至少一种在受损组织，如伤口环境中上调的特定不良蛋白质（例如特定蛋白酶）的作用。
• POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE
  申请人：Elysium Therapeutics, Inc.

  公开号：US20170100390A1

  公开（公告）日：2017-04-13

  The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.

  这项发明提供了用于治疗或预防疼痛的组合物和方法。该发明提供了构造物，通过指定的胃肠酶在口服时直接或间接地水解构造物释放阿片类物质。该发明中构造物中的胃肠酶介导的阿片类物质释放被设计为在体内通过饱和或抑制机制在摄入过量时减弱。该发明进一步提供了对口服过量、化学篡改和通过非口服途径滥用高度抵抗的构造物。
• Pyridine and pyrimidine derivatives
  申请人：——

  公开号：US20030216382A1

  公开（公告）日：2003-11-20

  The present invention provides compounds of formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 and X are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

  本发明提供了化合物的公式（I）1，其中R1、R2、R3、R4和X如规范中所定义，以及其药用盐。这些化合物可用于治疗和/或预防与DPP IV相关的疾病，如糖尿病，特别是非胰岛素依赖型糖尿病和糖耐量受损。
• [EN] AN ORGANIC ELECTROLUMINESCENT COMPOUND AND AN ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME<br/>[FR] COMPOSÉ ÉLECTROLUMINESCENT ORGANIQUE ET DISPOSITIF ÉLECTROLUMINESCENT ORGANIQUE COMPRENANT CE COMPOSÉ
  申请人：ROHM & HAAS ELECT MAT

  公开号：WO2016006925A1

  公开（公告）日：2016-01-14

  The present invention relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound according to the present invention can produce an organic electroluminescent device having low driving voltage, excellent current and power efficiencies, and remarkably improved driving lifespan.

  本发明涉及一种有机电致发光化合物和由其组成的有机电致发光器件。根据本发明的有机电致发光化合物可以制备出具有低驱动电压、优异的电流和功率效率以及显著改善的驱动寿命的有机电致发光器件。